Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NRXP |
---|---|---|
09:32 ET | 1980 | 2.66 |
09:34 ET | 1000 | 2.6594 |
09:38 ET | 1109 | 2.6 |
09:39 ET | 100 | 2.6234 |
09:43 ET | 217 | 2.6048 |
09:52 ET | 3000 | 2.635 |
09:56 ET | 900 | 2.6384 |
09:57 ET | 2008 | 2.6 |
09:59 ET | 200 | 2.6 |
10:03 ET | 888 | 2.645 |
10:06 ET | 296 | 2.61 |
10:17 ET | 2015 | 2.61 |
10:19 ET | 300 | 2.61 |
10:46 ET | 600 | 2.64 |
10:48 ET | 500 | 2.66 |
10:50 ET | 766 | 2.63 |
10:53 ET | 499 | 2.61 |
11:00 ET | 500 | 2.6184 |
11:20 ET | 2797 | 2.58 |
11:27 ET | 1961 | 2.58 |
11:36 ET | 1100 | 2.56 |
11:42 ET | 300 | 2.54 |
11:44 ET | 1949 | 2.54 |
11:51 ET | 569 | 2.58 |
11:58 ET | 168 | 2.58 |
12:34 ET | 500 | 2.5201 |
12:36 ET | 300 | 2.52 |
12:41 ET | 100 | 2.5301 |
12:43 ET | 100 | 2.5418 |
12:48 ET | 310 | 2.58 |
12:50 ET | 100 | 2.5301 |
01:12 ET | 2447 | 2.545 |
01:14 ET | 200 | 2.5552 |
02:38 ET | 600 | 2.52 |
02:40 ET | 200 | 2.51 |
02:44 ET | 125 | 2.5 |
02:45 ET | 100 | 2.5005 |
02:49 ET | 162 | 2.5 |
03:03 ET | 108 | 2.5 |
03:07 ET | 678 | 2.51 |
03:12 ET | 100 | 2.51 |
03:18 ET | 500 | 2.51 |
03:25 ET | 150 | 2.53 |
03:36 ET | 3170 | 2.5 |
03:38 ET | 4800 | 2.425 |
03:39 ET | 679 | 2.48 |
03:41 ET | 600 | 2.47 |
03:48 ET | 300 | 2.48 |
03:50 ET | 200 | 2.48 |
03:52 ET | 1555 | 2.46 |
03:54 ET | 500 | 2.48 |
03:56 ET | 1856 | 2.4886 |
03:57 ET | 400 | 2.49 |
03:59 ET | 940 | 2.49 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
NRX Pharmaceuticals Inc | 26.6M | -1.2x | --- |
Enlivex Therapeutics Ltd | 27.7M | -1.0x | --- |
Alterola Biotech Inc | 27.3M | -7.5x | --- |
Brainstorm Cell Therapeutics Inc | 29.1M | -1.1x | --- |
RenovoRx Inc | 27.2M | -1.6x | --- |
Lisata Therapeutics Inc | 29.2M | -1.4x | --- |
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $26.6M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 10.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.26 |
EPS | $-2.06 |
Book Value | $-0.14 |
P/E Ratio | -1.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.